Non-islet cell tumour hypoglycaemia (NICTH) is a relatively rare syndrome defined by the presence of a solid tumour and severe recurrent fasting hypoglycaemia, which develops despite low or immeasurable levels of serum insulin [1±4]. The tumours are believed to cause hypoglycaemia by increasing the insulin-like activity of the circulating insulin-like growth factor (IGF) system. Firstly, almost all tumours involved in NICTH have increased expression of IGF-II mRNA and contain elevated protein levels of big IGF-II, i. e. partially processed proIGF-II [4, 5] . Big IGF-II is present in small amounts in normal serum [6] , but highly elevated in serum from most patients with NICTH [7±9], and big IGF-II has been reported to have relatively high insulin-like activity in vitro [9] .
Summary Non-islet cell tumour hypoglycaemia (NICTH) is characterised by severe and recurrent fasting hypoglycaemia, and is usually caused by secretion of insulin-like growth factor-II (IGF-II) by the tumour. This induces secondary changes in the circulating levels of insulin, growth hormone (GH), and the IGF-binding proteins (IGFBPs), resulting in an increased insulin-like hypoglycaemic activity of IGF-II. A participating role of IGF-I is not established. We measured serum levels of free IGF-I and free IGF-II, total IGF-I, total IGF-II, big IGF-II and IGFBP-1, IGFBP-2 and IGFBP-3 in patients with NICTH before (n = 14) and after surgical removal of the tumour (n = 3). A control group (n = 20) was included for comparison. In NICTH patients, free IGF-II was 20-fold increased (26.8 ± 8.1 [mean ± SEM] vs. 1.3 ± 0.1 mg/l), and free IGF-I was four fold increased (2.8 ± 0.4 vs. 0.7 ± 0.1 mg/l), as compared to control subjects (p < 0.0001). In accordance with earlier observations levels of total IGF-I, total IGF-II, and IG-FBP-3 were decreased, whereas IGFBP-1 and IG-FBP-2 were increased in NICTH (all p-values < 0.05). The highly elevated levels of free IGF-I and free IGF-II most likely imply a considerable hypoglycaemic insulin-like activity, and may, by negative feedback explain the marked suppression of the GH/IGF-I axis observed in NICTH. Finally, free IGF-II seems to be a powerful biochemical marker in the diagnosis of NICTH. [Diabetologia (1998) 
41: 589±594]
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ternary 150 kilo Dalton (kDa) growth hormone (GH) dependent complex together with IGFBP-3 and a large non-IGF binding glycoprotein, the acid labile subunit (ALS). This complex is, due to its size, restricted to the circulation [5] . The remaining IGFs circulate almost exclusively as binary IGF:IGFBP complexes of about 30±50 kDa, leaving less than 1 % in the free form [11] . In NICTH, the secretion of GH is suppressed [3] , and this results in a reduction in the levels of the GH dependent peptides ALS, IGFBP-3 and IGF-I, and thus ternary complex formation [4, 12] . Levels of IGFBP-2, the second most abundant IGFBP, and IGFBP-1 are, on the other hand, increased [5, 13] . Whereas the mechanisms regulating IGFBP-2 are still unclear [14] , the increase in levels of IGFBP-1 is secondary to the hypoinsulinaemia [15] . Finally, the ability of big IGF-II:IGFBP-3 to combine with ALS forming the ternary complex is subnormal [9, 16] . These changes cause a shift in the molecular distribution of the IGFs, and in NICTH as much as 80 % of the circulating IGF-II is reported to be carried in the binary complexes and hence, to have access to the interstitial space [17] . It is likely that patients with NICTH have increased synthesis and turnover of IGF-II at the same time, and therefore only modest changes in the circulating levels of serum total IGF-II [2, 3] .
Our previous observations have suggested that free IGFs contribute only marginally to the glucohomeostasis in the normal state [18] . However, in NICTH free IGF-II most likely plays a major role. Daughaday et al. [12] recently reported that levels of ªfree IGF-IIº (determined by chromatography) were highly elevated in patients with NICTH and suggested that this largely explained the marked hypoglycaemia. Chromatography appears, however, not to be well suited for determination of free IGFs, primarily because it does not allow maintenance of the in vivo equilibrium between free and bound peptide [11] . We have, therefore, examined circulating levels of free and total IGFs and IGFBPs in preoperative and postoperative serum samples from patients with severe hypoglycaemia, measuring free IGF-I and free IGF-II using an ultrafiltration technique designed to obtain in vivo concentrations.
Subjects, materials and methods
We studied serum from 14 patients with NICTH; the available clinical data are listed in Table 1 . NICTH was defined by the concomitant presence of a large tumour, recurrent and severe hypoglycaemia and low or immeasurable levels of serum insulin. Big IGF-II levels in some of the patients have been published previously [9] , and primarily metabolic data from one patient has been published before [19] . The study included preoperative serum samples from 14 patients with NICTH, as well as preliminary data on 3 postoperative patients. For comparison, fasting serum samples obtained from 20 healthy sub- ±: not determined jects (10 females and 10 males) served as controls. This group was characterised by an age of 51 ± 1 (39±59) years (mean ± SEM [range]), a weight of 87 ± 3 (66±103) kg, a BMI of 29.7 ± 0.7 (25.2±37.1) kg/m 2 (NICTH patients are usually wellnourished), a normal fasting blood glucose of 4.4 ± 0.1 (3.5±5.6) mmol/l and a fasting serum insulin of 61 ± 8 (25±145) pmol/l. The study was conducted in accordance with the Helsinki Declaration with amendments.
All samples were analysed in duplicates unless otherwise stated. IGF-I and IGF-II were determined by two in-house non-competitive monoclonal antibody based time-resolved immunofluorometric assays (TR-IFMAs) [20] . These assays are characterised by high sensitivity (detection limit was 2.5 ng/l [IGF-I]) and 10 ng/l [IGF-II]) and specificity (the IGF-I and IGF-II cross reactivity in heterologous assays was < 0.0002 %). Serum total IGF-I and IGF-II were determined in acid ethanol serum extracts with a within-assay and in between-assay coefficient of variation (CV) averaging less than 5 % and 10 %, respectively [20] . In addition, serum big and total IGF-II were isolated using acid Biogel P-60 chromatography, and measured by RIA as previously described [9] . Serum free IGF-I and IGF-II were determined using ultrafiltration by centrifugation (Amicon YMT 30 ultrafiltration membranes and MPS-1 supporting devices, Amicon, Beverly, Mass., USA) [11] . Normally, serum from healthy subjects can be diluted 20 times in Krebs-Ringer bicarbonate buffer (pH 7.4, 50 g/l human serum albumin [HSA]) without changing the concentration of free IGF [11] . A pilot study performed on serum from a patient with NICTH showed, however, that in this case serum could not be diluted prior to ultrafiltration without altering the concentration of free IGF-II. In the undiluted state, the concentration of free IGF-II was 106 mg/l, but decreased to 53, 22 and 11 mg/l following a dilution of 1:5, 1:10 and 1:20, respectively. Similar observations have been made in experiments with rats, which are characterized by levels of free IGF-I that are approximately 100 times higher than in humans, i. e. in the range of what is observed in patients with NICTH [21] . Therefore, in samples from patients with NICTH, free IGF-I and IGF-II were determined in undiluted serum, whereas samples from the control subjects were diluted 1:11 as previously described [11] . Before centrifugation (at 37°C and 300 g), all samples were adjusted to pH 7.4 with CO 2 , and equilibrated for 30 min at 37°C. Controls were analysed in triplicates with a CV of 20.9 % (free IGF-I) and 24.7 % (free IGF-II). The volume of serum from patients with NICTH was sparse, and therefore, free IGF-I and IGF-II were analysed in single determinations. Serum free IGF-II was, however, analysed in 4 different dilutions (1:51, 1:102, 1:204 and 1:408). The CV of the 4 different dilutions averaged 20.0 %, and samples diluted in parallel with the calibration curve (data not shown). The ultrafiltrates obtained sufficed for determination of free IGF-I in 11 out of the 14 patients with NICTH only.
IGFBP-1 was measured by ELISA (Medix Biochemica, Kainiainen, Finland), IGFBP-2 and IGFBP-3 by RIA and immunoradiometric assay (IRMA) (Diagnostic System Laboratories Inc., Webster, Tex., USA), GH by TR-IFMA (Wallac Oy, Turku, Finland), and insulin by ELISA (Dako A/S, Glostrup, Denmark).
Statistical analysis. Patients with NICTH were compared to control subjects using Student's unpaired t-test (parametric data) or Mann Whitney's rank sum test (non-parametric data). Preoperative and postoperative samples from patients with NICTH were not statistically compared due to a limited number of subjects (n = 3). Data are given as mean ± SEM, and range when appropriate. A p-value less than 0.05 was considered statistically significant. 
Results
As expected, NICTH was characterised by markedly reduced insulin levels being below the fasting level of the controls (p < 0.0001) (Fig. 1A) . In all patients with NICTH the concentration of free IGF-II exceeded that of the control subjects (p < 0.0001) (Fig. 1A) . Free IGF-I was also significantly increased and above the upper limit of the controls in 8 out of 11 patients (p < 0.0001) (Fig. 1A) . Total IGF-I (p < 0.0001) (Fig. 1B) and total IGF-II (p < 0.02) (Fig. 1B) were significantly reduced in NICTH using the twosite monoclonal IGF TR-IFMAs. Big IGF-II (Fig. 1B) has previously been shown to be elevated in some of the NICTH patients included in this study: about 50 % of total IGF-II was accounted for by big IGF-II, whereas in normal serum only 10 % was present as big IGF-II [9] . Similar levels of total IGF-II were obtained using either RIA or TR-IFMA (p = 0.3), although some inconsistency was observed. In patients with NICTH, both IGFBP-1 (p < 0.02) and IGFBP-2 (p < 0.0001) were increased, whereas IGF-BP-3 was decreased (p < 0.0001), when compared to control subjects (Fig. 1C) . All individual data have been summarized in Table 1 . The preliminary postoperative data showed that removal of the tumour normalised free IGF-I and free IGF-II, big IGF-II [9] and total IGF-I, whereas total IGF-II remained unaltered within the normal range (Table 2) . In NICTH patients, free IGF-II was positively correlated with serum total IGF-II (TR-IFMA) (r = 0.75; p < 0.005) and serum IGFBP-2 (r = 0.61; p < 0.03). Levels of big IGF-II and free IGF-II were positively correlated after transformation of raw data to reciprocal values (r = 0.65; p < 0.02), whereas no significant correlations between levels of free IGF-I and big IGF-II, or between free IGF-I and free IGF-II were observed. These were, however, correlated in the control group (r = 0.71; p < 0.0005). Insulin and IGFBP-1 were inversely correlated in the control group only (r = ±0.57; p < 0.01).
Discussion
In the present study of patients with NICTH the preoperative level of free IGF-I and free IGF-II was highly elevated. Thus, both peptides may participate in provoking hypoglycaemia. The increase in free IGF-I is a novel observation, and may participate in the suppression of the GH/IGF-I axis seen in NICTH [2±4]. Our findings of decreased circulating levels of total IGF-I, total IGF-II and IGFBP-3 and of increased levels of big IGF-II, IGFBP-1 and IGFBP-2 are in accordance with previous observations [2±5].
Using reverse phase neutral Sep Pak chromatography [22] Daughaday et al. measured ªfree IGF-IIº in eight patients with NICTH and found levels ranging from approximately 120±310 mg/l, compared to a control level of 7±23 mg/l [12] . Both ranges are considerably higher than reported here, which may primarily be explained by methodological differences. Firstly, Sep Pak separation does not permit free IGFs to be isolated at in vivo conditions. Secondly, the isolated free IGFs may include some IGFBP-complexed IGFs, which are not completely separated on the neutral Sep Pak column [22] . Thirdly, it is likely that the Sep Pak column is able to extract bound IGFs from some of the labile IGF:IGFBP complexes. Thus, we believe that Sep Pak separation of free from bound IGFs results in an overestimation of free IGF levels, and that a normal level of 7±23 mg/l of free IGF-II is far too high. Because C-18 reverse phase cartridges appear to be less suited for determination of free IGFs, we developed an ultrafiltration method that enables us to isolate free IGFs at physiological conditions (temperature, pH and ionic composition) without grossly altering the in vivo equilibrium between free and IGFBP-complexed IGF [11] (ultrafiltration is regarded as the gold standard for determination of free thyroid hormones). With this technique we have previously shown that free IGF-I shows meaningful variations in certain physiological and pathophysiological situations [11, 23±25] .
So far, most studies of NICTH have explained the recurrent hypoglycaemia with increased levels of big IGF-II and with the shift in circulating IGF-II from the ternary 150 kDa to the binary 40 kDa complex. [5, 27, 28] .
Only recently free IGF-II has been suggested as being of major importance in provoking hypoglycaemia in NICTH [12] . Our results support and extend the theory to include free IGF-I as a possible cause of hypoglycaemia. In NICTH patients, the combined levels of free IGF-I plus free IGF-II ranged from about 3 to 127 mg/l as compared to 1±4 mg/l in normal control subjects. From in vitro studies in isolated mouse soleus muscle it appears that the half-maximal effect of IGF-I on glucose uptake, glycolysis and glycogen synthesis is between 35 and 80 mg/l [29] . Assuming a similar potency for IGF-II one would guess that serum levels of about 20 mg/l of free IGF, which were present in 8 out of 14 tumour patients, would be sufficient to cause hypoglycaemia. The mechanisms responsible for the elevated serum levels of free IGF-I and free IGF-II are not clear. We believe that the elevation is secondary to the increased synthesis of big IGF-II by the tumour, displacing IGF-I and IGF-II from the IGFBPs. This view is supported by the significant positive correlation between levels of free IGF-II and big IGF-II (r = 0.65; p < 0.02). However, further studies are needed.
Levels of free IGF-I were fourfold increased in patients with NICTH, when compared to control subjects, and these changes markedly contrasted with the sixfold reduction in total IGF-I. Free IGF-I was, however, not as grossly elevated as free IGF-II in the patients with NICTH, but the inhibitory effect of IGF-I on the pituitary is reported to be stronger than that of IGF-II [30, 31] . Therefore, both peptides may contribute to the marked suppression of GH, which may aggravate the hypoglycaemia.
Three patients with NICTH were studied postoperatively, and as judged from the measurements all patients underwent a successful tumour removal: levels either normalised or near-normalised. As observed in patient no. 10 these changes took place very rapidly.
In conclusion, this study gives further evidence for a pathogenic role of free IGF-II in tumour induced hypoglycaemia. In addition, the increased level of free IGF-I may in part, by negative feedback contribute to the suppressed GH secretion observed in NICTH. The study also shows that free IGF-II is a powerful biochemical discriminator in the diagnosis of NICTH.
